

PRESS RELEASE December 3, 2025

Paindrainer AB to be granted US patent for its unique patient-centric concept for chronic pain management

LUND, SWEDEN – Paindrainer AB, a pioneer in the field of digital healthcare technology, is pleased to announce that the United States Patent and Trademark Office has allowed Paindrainers unique proprietary platform for 360° patient-centric chronic pain management, powered by an artificial neural network, to be patentable.

At its core, this patent outlines a personalized pain-management platform that leverages users' own data and a neural network analysis to provide tailored recommendations. These recommendations are fully adaptive to each user, aiming to alleviate pain and enhance quality of life by adjusting behaviors or activities. The patent also provides a basis for pursuing additional protection for other indications.

"The successful grant of our patent in the US marks a significant milestone in our journey towards revolutionizing pain management. We have had our EPO patent granted for about a year and to see that the US Patent office decides in the same direction as the EPO shows that we provide a highly innovative system for the market. It also exemplifies our commitment to leveraging cutting-edge technology with the potential to enhance staff efficiency in pain clinics through remote monitoring, while improving patient retention and adherence to treatment plans. The approval means that we are effectively protecting the company's intangible assets in our highly important US market.", says Erik Frick, CEO Paindrainer AB.

Paindrainer AB collaborates with Potter Clarkson LLP IP law firm for strategies and applications.

"Following the successful prosecution of Paindrainer's European patent it is excellent to see that patent offices in other countries also recognising that Paindrainer's pain management tool is patentable. This international recognition of the advancements that the company are making can only help them continue to alleviate chronic pain for patients around the world. We really value our collaborative relationship with Paindrainer, and we appreciate the opportunity that it presents us with to play a small part in helping them achieve their goals.", says Dave Clark, Partner at Potter Clarkson.

The Paindrainer® mobile application is the first evidence-based digital tool demonstrating improved quality of life for individuals living with chronic pain. The product is classified as a Class I Software as a Medical Device (SaMD) and is 510(k) exempt. Paindrainer leverages advanced adaptive algorithms and a proprietary 360° patient-centric framework to help users better understand their activity patterns and make informed decisions that support improved daily functioning. Early real-world use and clinical evidence underpin the platform's value, positioning Paindrainer as a differentiated, scalable solution within the digital health and pain-management markets.



For more information, please contact:

Erik Frick
CEO Paindrainer AB
erik.frick@paindrainer.com
+46 736 61 21 23

About Paindrainer AB

Paindrainer AB is a company developing digital platforms and applications contributing to health and well-being. Paindrainer was founded in 2018 by Prof. Carl Borrebaeck, Dr. Maria Rosén Klement, and Göran Barkfors. The idea was born when Maria, after participating in several pain rehabilitation programs, realized that pain is affected by many more factors than the human brain can comprehend.

Paindrainer® is the first evidence-based AI powered digital tool demonstrating improved quality of life in patients suffering from chronic pain.

Paindrainer® coaches the users in managing their pain and planning their day and to ensure that there is enough energy left for highly valued activities. The solution is powered by leveraging advanced algorithms and is fully adaptive to each patient, a feature called 360° patient-centricity©.

Paindrainer® (PD Care System) is as a Class I Software as a Medical Device (SaMD) and is 510(k) exempt.

www.paindrainer.com